Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date
Sign Up to like & getrecommendations! Published in 2018 at "OncoTargets and therapy"
DOI: 10.2147/ott.s165511
Abstract: The identification of anaplastic lymphoma kinase (ALK), an oncogenetic driver mutation, in lung cancer has paved the way for a new era in the treatment of non-small cell lung cancer (NSCLC). Targeting ALK using tyrosine… read more here.
Keywords: alk; alk tki; treatment; spotlight lorlatinib ... See more keywords